[Recommendations for the healthcare of patients with FOP].

[1]  R. Pignolo,et al.  The Fibrodysplasia Ossificans Progressiva Physical Function Questionnaire (FOP-PFQ): A patient-reported, disease-specific measure. , 2022, Bone.

[2]  F. Kaplan,et al.  The impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members: results from an international burden of illness survey , 2022, Expert review of pharmacoeconomics & outcomes research.

[3]  F. Lobbezoo,et al.  Limitations of Jaw Movement in Fibrodysplasia Ossificans Progressiva: A Review , 2022, Frontiers in Medicine.

[4]  E. Hsiao,et al.  Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization , 2021, Orphanet Journal of Rare Diseases.

[5]  E. Hsiao,et al.  Cardiopulmonary and Neurologic Dysfunctions in Fibrodysplasia Ossificans Progressiva , 2021, Biomedicines.

[6]  R. Ravazzolo,et al.  Genomic Context and Mechanisms of the ACVR1 Mutation in Fibrodysplasia Ossificans Progressiva , 2021, Biomedicines.

[7]  F. Kaplan,et al.  The Developmental Phenotype of the Great Toe in Fibrodysplasia Ossificans Progressiva , 2020, Frontiers in Cell and Developmental Biology.

[8]  R. Pignolo,et al.  Epidemiology of the Global Fibrodysplasia Ossificans Progressiva (FOP) Community , 2020 .

[9]  H. Kitoh.  Clinical Aspects and Current Therapeutic Approaches for FOP , 2020, Biomedicines.

[10]  R. Pignolo,et al.  A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP). , 2017, Bone.

[11]  P. Landais,et al.  Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases , 2017, Orphanet Journal of Rare Diseases.

[12]  David M. Rocke,et al.  The Natural History of Flare‐Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  F. Kaplan,et al.  Inherited human diseases of heterotopic bone formation , 2010, Nature Reviews Rheumatology.

[14]  S. Mundlos,et al.  Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1 , 2009, Human mutation.

[15]  David M. Rocke,et al.  Iatrogenic Harm Caused by Diagnostic Errors in Fibrodysplasia Ossificans Progressiva , 2005, Pediatrics.

[16]  G. Finkel,et al.  The histopathology of fibrodysplasia ossificans progressiva. An endochondral process. , 1993, The Journal of bone and joint surgery. American volume.

[17]  In Ho Choi,et al.  A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva , 2006, Nature Genetics.